Placeholder

Creating the Message in Phase II Trials

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

Decisions made in Phase II trials can have an impact on the development and marketing program for new products, and experts say Phase II is becoming a critical stage for planning the potential launch and marketing of products.
Bringing agencies in earlier in the process makes a lot of sense, says Abby Mansfield, senior VP and creative director at Topin & Associates.

Sidebar:
Best Practices for Phase II Efficiency

Experts
Jennifer Brice. Life Sciences Global Program Manager, Frost & Sullivan, which provides ­research and best-practice ­models to drive the generation, evaluation, and implementation of growth strategies. For more information, visit frost.com.
Chris Garabedian. President and CEO, AVI BioPharma Inc., which is focused on the ­discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. For more information,
visit avibio.com.
Abby Mansfield. Senior VP, ­Creative Director, Topin & ­Associates Inc., a healthcare ­marketing agency that specializes in strategic marketing for healthcare, medical, and pharmaceutical clients. For more ­information, visit topin.com.
Ken Ribotsky. President and CEO, The Core Nation, a family of ­healthcare marketing and medical communications companies
(Core-Create, Brandkarma, and Alpha & Omega) that offers strategic, branding, and creative ­consulting services. For more ­information, visit thecorenation.com.

FEEDBACK